These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22217982)

  • 21. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast abnormalities in the pathogenesis of systemic sclerosis.
    Usategui A; del Rey MJ; Pablos JL
    Expert Rev Clin Immunol; 2011 Jul; 7(4):491-8. PubMed ID: 21790292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunobiology of systemic sclerosis.
    Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
    Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of dermal connective tissue in scleroderma.
    Kähäri VM
    Ann Med; 1993 Dec; 25(6):511-8. PubMed ID: 8292298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Systemic sclerosis--clinical course and treatment possibilities].
    Szymańska E; Maj M; Rudnicka L
    Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel insights on the role of the innate immune system in systemic sclerosis.
    York MR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):481-9. PubMed ID: 21790291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.
    Sunderkötter C; Riemekasten G
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
    Fuschiotti P; Medsger TA; Morel PA
    Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenic cytokines and growth factors in systemic sclerosis.
    Liakouli V; Cipriani P; Marrelli A; Alvaro S; Ruscitti P; Giacomelli R
    Autoimmun Rev; 2011 Aug; 10(10):590-4. PubMed ID: 21549861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired growth response to endothelin-1 in scleroderma fibroblasts.
    Kikuchi K; Kadono T; Sato S; Tamaki K; Takehara K
    Biochem Biophys Res Commun; 1995 Feb; 207(2):829-38. PubMed ID: 7864878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Characteristic of the endogenous peptides--endothelins and their role in the connective tissue fibrosis].
    Garncarczyk A; Jurzak M; Gojniczek K
    Wiad Lek; 2008; 61(4-6):126-34. PubMed ID: 18939363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of skin fibrosis in systemic sclerosis.
    Jinnin M
    J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systemic sclerosis (scleroderma): etiology and pathogenesis--where are we today?].
    Stoll T; Brühlmann P; Fontana A; Gmür J; Michel BA
    Schweiz Med Wochenschr; 1994 Feb; 124(5):193-203. PubMed ID: 8128201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular complications of scleroderma.
    Guiducci S; Giacomelli R; Cerinic MM
    Autoimmun Rev; 2007 Sep; 6(8):520-3. PubMed ID: 17854742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic susceptibility to systemic sclerosis from clinical aspect to genetic factor analyses.
    Granel B; Bernard F; Chevillard C
    Eur J Intern Med; 2009 May; 20(3):242-52. PubMed ID: 19393491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis.
    Verrecchia F; Mauviel A; Farge D
    Autoimmun Rev; 2006 Oct; 5(8):563-9. PubMed ID: 17027893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.